E-6742
- Generic Name
- E-6742
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E6742 in Systemic Lupus Erythematosus Participants
- First Posted Date
- 2022-03-14
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 26
- Registration Number
- NCT05278663
- Locations
- 🇯🇵
Daido Clinic, Nagoya, Aichi, Japan
🇯🇵Tohoku University Hospital, Sendai, Miyagi, Japan
🇯🇵Hospital of the University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan
A Study to Assess the Safety and Tolerability of E6742 in Japanese Healthy Adult Participants
- First Posted Date
- 2020-12-24
- Last Posted Date
- 2021-07-20
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT04683185
- Locations
- 🇯🇵
Eisai Trial Site #1, Bunkyō-Ku, Tokyo, Japan
Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742 in Healthy Adult Subjects
- First Posted Date
- 2017-03-17
- Last Posted Date
- 2018-09-07
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT03082235
- Locations
- 🇺🇸
Parexel International, Glendale, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath